Jenny Harrington, CEO, Gilman Hill Asset Management Organon OGN-N BUY Jul 14, 2023

Spun off from Merck two years, but has been sitting in the penalty box. Pays a 5.5% dividend at 5x earnings.

Jenny Harrington, CEO, Gilman Hill Asset Management

Unknown

Unlock Rating

$20.585

Stock price when the opinion was issued

Pharma & Healthcare

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

It has no growth.

DON'T BUY

Recently on a downward trend. Fundamentally scores 3/10. Would not recommend buying. Price target falling. Has not been able to beat earnings. Better options available for investors. High debt levels not good for dividend outlook.

Most Recent Experts

Brian Madden

First Avenue Investment Counsel

Stockchase Insights

5i Research